Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.
The call featured remarks from chief executive Jacqueline Shea and other executives. Participants highlighted the ongoing FDA review of the biologics license application for INO-3107, which carries a PDUFA target date of October 30, 2026. The company also noted plans for a future meeting with regulators to address potential eligibility for the accelerated approval pathway, citing its view that the product meets the necessary criteria.